Kamada’s aerosolized Alpha-1 Antitrypsin product is currently undergoing Phase II clinical trials.
David Tsur, CEO of Kamada, said: “This significant recognition grants Kamada various benefits such as research fund support, tax incentives, reduced user fees and seven years of exclusive distribution rights, if the company’s product is first on the US market for this indication.”